^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Purinergic receptor P2Y12 inhibitor

    Related drugs:
    1d
    INTERPRET: INsTantenous wavE-Free Ratio-guided PCI Versus Fractional Flow REserve-Guided PCI in rouTine Clinical Practice, Prospective, Multicenter Registry (clinicaltrials.gov)
    P=N/A, N=1200, Active, not recruiting, Samsung Medical Center | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    3d
    Efficacy of ticagrelor and clopidogrel in treating unstable angina and their effects on serum inflammatory factors. (PubMed, Pak J Pharm Sci)
    The levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinase-9 (MMP-9), lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), type 1 tissue plasminogen activator inhibitor (tPAI-1), homocysteine (Hcy), endothelin-1 (ET-1), tumor necrosis factor-alpha (TNF-α), platelet-derived growth factor (PDGF), brain natriuretic peptide (BNP), soluble CD40 ligand (sCD40L), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule (sLCAM-1), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglycerides (TG), as well as the incidence of MACCE events, were all lower in the Ticagrelor group compared to the Clopidogrel group (P<0.05), while high-density lipoprotein cholesterol (HDL-C) levels and overall efficacy were higher in the Ticagrelor group (P<0.05). Ticagrelor demonstrates superior therapeutic efficacy compared to Clopidogrel in patients with coronary heart disease and unstable angina, effectively reducing serum inflammatory factor levels.
    Clinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL18 (Interleukin 18) • MMP9 (Matrix metallopeptidase 9) • CD40LG (CD40 ligand) • VCAM1 (Vascular Cell Adhesion Molecule 1) • CRP (C-reactive protein) • MPO (Myeloperoxidase) • NPPB (Natriuretic Peptide B)
    6d
    DOSE: Randomized Comparison of Radiation Exposure to Operators in Coronary Intervention Between Right Radial and Left DRA (clinicaltrials.gov)
    P=N/A, N=1010, Active, not recruiting, Yonsei University | Recruiting --> Active, not recruiting
    Enrollment closed
    7d
    The antitumor effects of metformin are potentially mediated through LPA receptor inhibition. (PubMed, Diabetes Res Clin Pract)
    These results indicate that the inhibition of LPA receptor signaling by metformin, especially the consequent suppression of LPAR3-mediated cell migration, may contribute to the antitumor effects of metformin.
    Journal
    |
    EGF (Epidermal growth factor) • LPAR3 (Lysophosphatidic Acid Receptor 3)
    |
    metformin • YM-254890
    7d
    Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas (clinicaltrials.gov)
    P2/3, N=100, Active, not recruiting, University of Sao Paulo
    New P2/3 trial
    7d
    SPRING: Effectivity and Safety of PFO Closure Vs Medicine in Alleviating Migraine (clinicaltrials.gov)
    P3, N=440, Active, not recruiting, Guangdong Provincial People's Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2024 --> Sep 2025
    Enrollment closed • Trial primary completion date
    9d
    ADAPT AFFIRM: Antithrombotic Strategy for AF Patients With High Risk CAD (clinicaltrials.gov)
    P=N/A, N=1400, Not yet recruiting, Yonsei University
    New trial
    16d
    PATH STROKE C: Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients with Acute Ischemic STROKE (clinicaltrials.gov)
    P3, N=5138, Not yet recruiting, Sichuan Provincial People's Hospital
    New P3 trial
    29d
    CAMEO: Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry (clinicaltrials.gov)
    P=N/A, N=4000, Active, not recruiting, Chiesi USA, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    1m
    ECISBI: Efficacy of Clopidogrel on Incidence of Silent Brain Infarction (clinicaltrials.gov)
    P4, N=125, Recruiting, VA Office of Research and Development | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    1m
    The Switching Antiplatelet-9 (SWAP-9) Study (clinicaltrials.gov)
    P4, N=90, Recruiting, University of Florida | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    A2B adenosine receptor-triggered intracellular calcium mobilization: Cell type-dependent involvement of Gi, Gq, Gs proteins and protein kinase C. (PubMed, Purinergic Signal)
    We and others reported that Gαq/11 inhibitor FR900359 (FR) can inhibit both Gαq- and, surprisingly, Giβγ-mediated intracellular Ca2+ mobilization...However, in T24 bladder cancer cells, Gi inhibitor PTX, but not Gαq/11 inhibitors, FR, YM254890 (YM) or Gq/11 siRNA, inhibited Ca2+ increase triggered by native A2BAR activation...Thus, Gαq/11 is vital for Ca2+ increase in some cell types, but Giβγ-mediated Ca2+ signaling can be Gαq/11-dependent or independent based on cell type and receptor activated. Besides G proteins, PKC also modulates cytosolic Ca2+ increase depending on cell type and receptor.
    Journal
    |
    ARRB1 (Arrestin Beta 1)
    |
    YM-254890 • FR900359
    1m
    Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study - The Switching Antiplatelet-8 (SWAP-8) Study (clinicaltrials.gov)
    P4, N=78, Not yet recruiting, University of Florida
    New P4 trial
    1m
    FACTPCI: Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention (clinicaltrials.gov)
    P4, N=38, Terminated, The Guthrie Clinic | N=80 --> 38 | Trial completion date: Dec 2026 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jan 2025; Researcher stopped study due to slow accrual rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    1m
    TAILOR BLEED: Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (clinicaltrials.gov)
    P4, N=90, Recruiting, University of Florida | Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    2ms
    SWAP-7: Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors (clinicaltrials.gov)
    P4, N=48, Recruiting, University of Florida | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents (clinicaltrials.gov)
    P4, N=960, Active, not recruiting, Yonsei University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    2ms
    Long-term Dual Antiplatelet Therapy Reduces Intracranial Atherosclerotic Plaque Burden: A Prospective, Multicenter, Open-label, Single-blind, Randomized Controlled Clinical Trial (ChiCTR2500095357)
    P=N/A, N=100, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    2ms
    A multicenter randomized, double-blind, placebo-controlled, Phase III clinical trial to confirm the efficacy and safety of Batifeiban injection in patients with ACS undergoing PCI (ChiCTR2400092377)
    P3, N=1750, Completed, Zhongshan Hospital, Fudan University; Bio-Thera Solutions, Co., Ltd
    New P3 trial
    2ms
    BRAVE: Bariatric Surgery for the Reduction of CArdioVascular Events Randomized Controlled Trial (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Population Health Research Institute | N=2000 --> 200
    Enrollment change
    2ms
    Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA (clinicaltrials.gov)
    P3, N=900, Recruiting, Kafrelsheikh University | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    aspirin
    2ms
    GUIDE-HBR: Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients with ACS and HBR (clinicaltrials.gov)
    P4, N=3000, Not yet recruiting, Samsung Medical Center
    New P4 trial
    2ms
    Evaluation of the Efficacy of Novel Biomarkers in Predicting Clopidogrel Resistance in Patients with Ischemic Stroke (clinicaltrials.gov)
    P=N/A, N=800, Not yet recruiting, Nanjing First Hospital, Nanjing Medical University
    New trial
    2ms
    FACTPCI: Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention (clinicaltrials.gov)
    P4, N=80, Recruiting, The Guthrie Clinic | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    3ms
    Evaluation of the Efficacy of Novel Biomarkers in Predicting Clopidogrel Resistance in Patients with Ischemic Stroke (clinicaltrials.gov)
    P=N/A, N=800, Not yet recruiting, Nanjing First Hospital, Nanjing Medical University
    New trial
    3ms
    ATIS-NVAF: Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis (clinicaltrials.gov)
    P4, N=321, Terminated, National Hospital Organization Osaka National Hospital | Recruiting --> Terminated; The trial was terminated at the planned interim analysis for futility on July 18, 2023.
    Trial termination
    3ms
    A2B adenosine receptor-triggered intracellular calcium mobilization: Cell type-dependent involvement of Gi, Gq, Gs proteins and protein kinase C. (PubMed, Res Sq)
    However, in T24 bladder cancer cells, G i inhibitor PTX, but not G αq/11 inhibitors, FR, YM254890 (YM) or G q/11 siRNA, inhibited Ca 2+ increase triggered by native A 2B AR activation...Thus, G αq/11 is vital for Ca 2+ increase in some cell types, but G iβγ -mediated Ca 2+ signaling can be Gα q/11 -dependent or independent based on cell type and receptor activated. Besides G proteins, PKC also modulates cytosolic Ca 2+ increase depending on cell type and receptor.
    Journal
    |
    ARRB1 (Arrestin Beta 1)
    |
    YM-254890
    3ms
    RELIEF: GORE® CARDIOFORM Septal Occluder Migraine Clinical Study (clinicaltrials.gov)
    P=N/A, N=7, Terminated, W.L.Gore & Associates | Trial completion date: Aug 2026 --> Aug 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Aug 2024; Dissatisfactory enrollment rate with no safety concerns
    Trial completion date • Trial termination • Trial primary completion date
    3ms
    READAPT: A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA (clinicaltrials.gov)
    P=N/A, N=2239, Completed, University of L'Aquila | Recruiting --> Completed | N=1067 --> 2239
    Trial completion • Enrollment change
    4ms
    POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy (clinicaltrials.gov)
    P2, N=200, Recruiting, St. Antonius Hospital | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial completion date • Trial primary completion date
    4ms
    NUANCE-ICAD: Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection Vs Conventional Clopidogrel Therapy in Symptomatic ICAD (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Sunnybrook Health Sciences Centre
    New trial
    4ms
    Precision PCI Registry (clinicaltrials.gov)
    P=N/A, N=1643, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Jan 2025 --> Jul 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    4ms
    Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel (clinicaltrials.gov)
    P1, N=24, Recruiting, Washington State University
    New P1 trial
    4ms
    SWAP-7: Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors (clinicaltrials.gov)
    P4, N=48, Not yet recruiting, University of Florida
    New P4 trial
    4ms
    Dual Antiplatelet Therapy Adherence With Reminder App Usage (clinicaltrials.gov)
    P=N/A, N=9, Terminated, Montefiore Medical Center | N=68 --> 9 | Trial completion date: Dec 2030 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2030 --> Jul 2024; The PI is discontinuing the study since the platform/Application is no longer available for use. Study terminated effective 7/29/2024.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Adherence
    4ms
    TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4. (PubMed, Drug Resist Updat)
    Mechanistically, TMOD3 promoted F-actin polymerization, thereby facilitating the fusion of autophagosomes with lysosomes, increasing the degradation of the ACSL4 protein, and augmenting the ferroptosis-inducing effects of RSL3...Cangrelor, an FDA-approved drug, can target TMOD3...In conclusion, TMOD3 was found to inhibit ferroptosis and induced the resistance to PD-1 antibody by facilitating the fusion of autophagosomes and lysosomes through the promotion of F-actin polymerization in KRAS-mutant PC. TMOD3 was identified as a novel target for PC therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4)
    |
    KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression
    |
    RSL3
    4ms
    Study on Effect of Pharmacogenomics-based Point-of-Care Testing on Guiding Precise Antiplatelet and Lipid-lowering Therapies for Acute Ischemic Stroke Patients after rtPA Thrombolysis (ChiCTR2400090813)
    P=N/A, N=1092, Not yet recruiting, Dalian Municipal Central Hospital; Dalian Municipal Central Hospital
    New trial
    |
    atorvastatin
    4ms
    Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with cute minor ischemic stroke with CYP2C19 gene function deficiency: A multicenter, open label, and efficacy randomized controlled study (ChiCTR2400091121)
    P4, N=1050, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New P4 trial
    |
    aspirin
    4ms
    BRLCEIACS/OMI: Brilinta Clinical Experience Investigation (clinicaltrials.gov)
    P=N/A, N=663, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Mar 2028 --> Jul 2024 | Trial primary completion date: Mar 2028 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date
    5ms
    ODIN: One-Month DAPT in CABG Patients (clinicaltrials.gov)
    P3, N=700, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    aspirin
    5ms
    Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST) (clinicaltrials.gov)
    P4, N=1022, Completed, General Hospital of Shenyang Military Region | Recruiting --> Completed
    Trial completion
    5ms
    A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial (clinicaltrials.gov)
    P4, N=3200, Active, not recruiting, Yonsei University
    Trial completion date • Trial primary completion date